thromboxane-a2 and Infections

Mild to moderate hypothermia (32-35 degrees C) is the first treatment with proven efficacy for postischemic neurological injury. In recent years important insights have been gained into the mechanisms underlying hypothermia's protective effects; in addition, physiological and pathophysiological changes associated with cooling have become better understood.. To discuss hypothermia's mechanisms of action, to review (patho)physiological changes associated with cooling, and to discuss potential side effects.. Review article.. None.. A myriad of destructive processes unfold in injured tissue following ischemia-reperfusion. These include excitotoxicty, neuroinflammation, apoptosis, free radical production, seizure activity, blood-brain barrier disruption, blood vessel leakage, cerebral thermopooling, and numerous others. The severity of this destructive cascade determines whether injured cells will survive or die. Hypothermia can inhibit or mitigate all of these mechanisms, while stimulating protective systems such as early gene activation. Hypothermia is also effective in mitigating intracranial hypertension and reducing brain edema. Side effects include immunosuppression with increased infection risk, cold diuresis and hypovolemia, electrolyte disorders, insulin resistance, impaired drug clearance, and mild coagulopathy. Targeted interventions are required to effectively manage these side effects. Hypothermia does not decrease myocardial contractility or induce hypotension if hypovolemia is corrected, and preliminary evidence suggests that it can be safely used in patients with cardiac shock. Cardiac output will decrease due to hypothermia-induced bradycardia, but given that metabolic rate also decreases the balance between supply and demand, is usually maintained or improved. In contrast to deep hypothermia (

Topics: Acidosis; Apoptosis; Body Temperature Regulation; Brain Edema; Brain Ischemia; Calpain; Critical Care; Epilepsy; Free Radicals; Genes, Immediate-Early; Humans; Hypothermia, Induced; Infections; Inflammation; Ion Pumps; Mitochondria; Reperfusion Injury; Thrombosis; Thromboxane A2

Topics: beta-Thromboglobulin; Biocompatible Materials; Blood Coagulation; Blood Platelets; Cell Adhesion; Fibrin; Humans; Infections; Kidney Failure, Chronic; Leukocytes; Leukopenia; Lymphocyte Activation; Membranes, Artificial; Platelet Activation; Platelet Adhesiveness; Platelet Factor 4; Polymethyl Methacrylate; Renal Dialysis; Respiratory Burst; Thrombin; Thromboxane A2

Topics: Animals; Burns; Capillary Permeability; Dogs; Epoprostenol; Hypertension, Pulmonary; Infections; Microcirculation; Prostaglandin Antagonists; Prostaglandins; Pulmonary Circulation; Pulmonary Embolism; Pulmonary Valve Insufficiency; Sheep; Shock, Hemorrhagic; Thromboxane A2